BPAX and ANI are voting on their merger on March 15th. Once that merger is behind, the combined company can focus on P3 new design of the Libigel with FDA. Soon after that P3 study should get going.... Back in 2011 Libigel failure shaved off $1 immediately from ATRS price which tells me that ATRS may gain a dollar once P3 study is under way. That should happen by the end of this year. Who wouldn't want a bump of $1 come Dec 2013?
Of course if P3 comes successful it would immediately add couple dollars. Libigel is a blockbuster drug with over 1Billion in just US sales;;;But the greatest part is that ATRS owns the rights for the rest of the world